NASDAQ : SILO
Silo Pharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.25 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Silo Pharma, Inc. (SILO) reported revenue of 54.08K USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Operating Revenue | 54.08K | 72.10K | 72.10K | 72.10K | 72.10K | 71.26K |
| Revenue | 54.08K | 72.10K | 72.10K | 72.10K | 72.10K | 71.26K |
| Cost of Revenue | 62.06K | 44.30K | 5.84K | 5.84K | 5.84K | 5.00K |
| Gross Profit | -7.99K | 27.81K | 66.26K | 66.26K | 66.26K | 66.26K |
| Selling, General & Admin | 2.29M | 2.15M | 2.40M | 3.08M | 2.43M | 2.27M |
| Research & Development | 2.16M | 2.16M | 2.37M | 845.09K | 1.29M | 693.91K |
| Operating Expenses | 4.45M | 4.31M | 4.77M | 3.92M | 3.71M | 2.96M |
| Operating Income | -4.46M | -4.28M | -4.71M | -3.86M | -3.65M | -2.89M |
| Interest Expense | -39.83K | -37.30K | -5.08K | -4.87K | -2.20K | -3.04K |
| Interest & Investment Income | 165.04K | 193.91K | 333.17K | 398.53K | 72.64K | 1.21K |
| Currency Exchange Gain (Loss) | -3.59K | -14.24K | ||||
| Other Non Operating Income (Expenses) | -224.11K | -104.32K | ||||
| EBT Excluding Unusual Items | -4.56M | -4.23M | -4.39M | -3.46M | -3.58M | -2.89M |
| Gain (Loss) on Sale of Investments | 518.00 | 671.00 | -1.02K | -3.12K | -435.90K | 6.91M |
| Other Unusual Items | 91.64K | -166.03K | 105.73K | 167.58K | ||
| Pretax Income | -4.47M | -4.23M | -4.39M | -3.63M | -3.91M | 4.18M |
| Income Tax Expense | 24.88K | |||||
| Earnings From Continuing Operations | -4.47M | -4.23M | -4.39M | -3.63M | -3.91M | 4.16M |
| Earnings From Discontinued Operations | -69.60K | -1.16K | -253.37K | |||
| Net Income | -4.47M | -4.23M | -4.39M | -3.70M | -3.91M | 3.90M |
| Preferred Dividends & Other Adjustments | 1.40M | |||||
| Net Income to Common | -4.47M | -4.23M | -4.39M | -3.70M | -3.91M | 2.50M |
| Shares Outstanding (Basic) | 882.60K | 558.82K | 245.36K | 205.32K | 152.28K | 126.49K |
| Shares Outstanding (Diluted) | 882.60K | 558.82K | 245.36K | 205.32K | 152.28K | 127.90K |
| EPS (Basic) | -5.07 | -7.57 | -17.90 | -18.02 | -25.67 | 19.76 |
| EPS (Diluted) | -5.07 | -7.57 | -17.90 | -18.02 | -25.67 | 19.52 |
| Gross Margin | -14.77% | 38.57% | 91.90% | 91.90% | 91.90% | 92.98% |
| Operating Margin | -8,250.46% | -5,936.95% | -6,526.44% | -5,347.41% | -5,059.02% | -4,059.33% |
| Profit Margin | -8,269.53% | -5,863.50% | -6,092.59% | -5,132.57% | -5,420.86% | 3,507.72% |
| EBITDA | -4.45M | -4.27M | -4.70M | |||
| D&A For EBITDA | 11.75K | 11.44K | 6.18K | |||
| EBIT | -4.46M | -4.28M | -4.71M | -3.86M | -3.65M | -2.89M |
| Effective Tax Rate | 0.60% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.28M | 4.75M | 3.91M | 3.52M | 11.37M | 9.84M |
| Short-Term Investments | 1.95M | 2.11M | 3.17M | 4.14M | 3.12K | 420.00K |
| Cash & Short-Term Investments | 5.23M | 6.86M | 7.08M | 7.67M | 11.37M | 10.26M |
| Accounts Receivable | 2.98K | 838.00 | 838.00 | 838.00 | 838.00 | |
| Receivables | 2.98K | 838.00 | 838.00 | 66.85K | 838.00 | |
| Prepaid Expenses | 280.87K | 187.87K | 25.12K | 10.13K | 119.20K | 59.97K |
| Other Current Assets | 205.41K | 338.11K | 5.00K | 5.00K | 15.86K | 84.52K |
| Total Current Assets | 5.71M | 7.39M | 7.11M | 7.68M | 11.57M | 10.40M |
| Other Intangible Assets | 211.50K | 217.38K | 241.22K | |||
| Long-Term Accounts Receivable | 8.52K | 9.36K | 10.20K | 11.03K | ||
| Long-Term Deferred Charges | 27.00K | 50.62K | 55.62K | 60.62K | 15.62K | |
| Total Assets | 5.95M | 7.61M | 7.41M | 7.75M | 11.64M | 10.49M |
| Accounts Payable | 362.18K | 578.08K | 1.58M | 703.49K | 220.61K | 417.94K |
| Accrued Expenses | 143.61K | |||||
| Current Unearned Revenue | 72.10K | 72.10K | 72.10K | 72.10K | 72.10K | |
| Total Current Liabilities | 1.07M | 650.18K | 1.66M | 775.59K | 436.32K | 490.04K |
| Long-Term Unearned Revenue | 649.48K | 721.58K | 793.68K | 865.78K | 937.88K | |
| Total Liabilities | 1.07M | 1.30M | 2.38M | 1.57M | 1.30M | 1.43M |
| Common Stock | 113.00 | 1.33K | 449.00 | 316.00 | 316.00 | 197.00 |
| Additional Paid-In Capital | 26.85M | 25.79M | 20.30M | 17.53M | 17.51M | 12.32M |
| Retained Earnings | -21.97M | -19.49M | -15.26M | -10.87M | -7.17M | -3.26M |
| Treasury Stock | -471.12K | |||||
| Comprehensive Income & Other | 6.83K | 5.83K | 2.42K | -6.23K | ||
| Total Common Equity | 4.89M | 6.31M | 5.03M | 6.18M | 10.34M | 9.06M |
| Shareholders' Equity | 4.89M | 6.31M | 5.03M | 6.18M | 10.34M | 9.06M |
| Total Liabilities & Equity | 5.95M | 7.61M | 7.41M | 7.75M | 11.64M | 10.49M |
| Net Cash (Debt) | 5.23M | 6.86M | 7.08M | 7.67M | 11.37M | 10.26M |
| Net Cash Per Share | 5.92 | 12.27 | 28.86 | 37.33 | 74.66 | 80.20 |
| Filing Date Shares Outstanding | 1.59M | 944.44K | 298.96K | 189.58K | 210.59K | 131.56K |
| Total Common Shares Outstanding | 1.13M | 887.88K | 298.96K | 193.75K | 210.59K | 131.52K |
| Working Capital | 4.65M | 6.74M | 5.46M | 6.91M | 11.14M | 9.91M |
| Book Value Per Share | 4.33 | 7.10 | 16.84 | 31.88 | 49.10 | 68.91 |
| Tangible Book Value | 4.67M | 6.09M | 4.79M | 6.18M | 10.34M | 9.06M |
| Tangible Book Value Per Share | 4.14 | 6.86 | 16.03 | 31.88 | 49.10 | 68.91 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -4.47M | -4.23M | -4.39M | -3.70M | -3.91M | 3.90M |
| Depreciation & Amortization | 11.75K | 11.44K | 6.18K | |||
| Loss (Gain) From Sale of Investments | -518.00 | -671.00 | 1.02K | 3.12K | 435.90K | -6.91M |
| Stock-Based Compensation | 1.52M | 635.25K | 104.19K | 70.31K | 191.70K | |
| Provision & Write-off of Bad Debts | -20.00K | -148.50K | ||||
| Other Operating Activities | 132.46K | 104.32K | -19.08K | |||
| Change in Accounts Payable | -523.97K | -993.41K | 633.01K | 339.27K | -53.72K | 291.05K |
| Change in Unearned Revenue | -54.08K | -72.10K | -72.10K | -72.10K | -72.10K | 478.74K |
| Change in Other Net Operating Assets | 49.21K | -118.46K | -9.15K | 32.10K | 50.53K | -40.07K |
| Operating Cash Flow | -3.34M | -4.66M | -3.83M | -3.22M | -3.50M | -2.28M |
| Investment in Securities | 124.14K | 1.22M | 973.78K | -4.15M | 66.71K | 7.02M |
| Other Investing Activities | -579.72K | -574.92K | 20.00K | 172.00K | ||
| Investing Cash Flow | -455.59K | 644.02K | 973.78K | -4.15M | 86.71K | 7.19M |
| Short-Term Debt Issued | 2.37K | |||||
| Total Debt Issued | 2.37K | |||||
| Short-Term Debt Repaid | -2.37K | |||||
| Total Debt Repaid | -2.37K | |||||
| Issuance of Common Stock | 2.77M | 4.86M | 3.41M | 4.94M | ||
| Repurchase of Common Stock | -173.11K | -471.12K | ||||
| Other Financing Activities | -27.00K | -481.90K | ||||
| Financing Cash Flow | 2.74M | 4.86M | 3.24M | -471.12K | 4.94M | 3.79M |
| Net Cash Flow | -1.06M | 842.90K | 381.49K | -7.84M | 1.53M | 8.71M |
| Levered Free Cash Flow | -1.64M | -3.56M | -2.07M | -1.78M | -2.24M | -1.10M |
| Unlevered Free Cash Flow | -1.62M | -3.53M | -2.07M | -1.78M | -2.23M | -1.10M |
| Cash Interest Paid | 39.83K | 37.30K | 5.08K | 4.87K | 2.20K | |
| Cash Income Tax Paid | 25.16K | |||||
| Change in Working Capital | -528.84K | -1.18M | 551.76K | 299.27K | -75.29K | 729.71K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.99M | 4.53M | 3.99M | 4.36M | 10.55M | 14.06M |
| Enterprise Value | -3.23M | -1.34M | -4.02M | -4.41M | -1.78M | 2.98M |
| Last Close Price | 1.23 | 5.10 | 13.35 | 21.60 | 50.40 | 106.87 |
| PE Ratio | 5.62 | |||||
| PS Ratio | 36.13 | 62.80 | 55.35 | 60.50 | 146.27 | 197.30 |
| PB Ratio | 0.28 | 0.72 | 0.79 | 0.71 | 1.02 | 1.55 |
| P/TBV Ratio | 0.42 | 0.74 | 0.83 | 0.71 | 1.02 | 1.55 |
| EV/Sales Ratio | 41.80 | |||||
| Net Debt / Equity Ratio | -1.07 | -1.09 | -1.41 | -1.24 | -1.10 | -1.13 |
| Net Debt / EBITDA Ratio | 1.18 | 1.61 | 1.51 | |||
| Asset Turnover | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Quick Ratio | 4.91 | 10.55 | 4.28 | 9.88 | 26.06 | 20.93 |
| Current Ratio | 5.36 | 11.36 | 4.29 | 9.90 | 26.52 | 21.23 |
| Return on Equity (ROE) | -91.23% | -74.56% | -78.37% | -43.97% | -40.28% | 80.38% |
| Return on Assets (ROA) | -44.25% | -35.63% | -38.80% | -24.86% | -20.60% | -30.34% |
| Return on Capital Employed (ROCE) | -91.30% | -61.50% | -81.80% | -55.30% | -32.50% | -28.90% |
| Earnings Yield | -403.72% | -93.36% | -110.06% | -84.83% | -37.06% | 27.76% |
| Buyback Yield / Dilution | -170.50% | -127.75% | -19.50% | -34.83% | -19.07% | -45.44% |